--- title: "Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Needham & Company LLC" type: "News" locale: "en" url: "https://longbridge.com/en/news/293471721.md" description: "Needham & Company LLC initiated coverage on Immix Biopharma (NASDAQ:IMMX) with a 'buy' rating and a $21.00 price target, implying an 119.44% upside. This follows similar positive ratings from Morgan Stanley, Citigroup, Lifesci Capital, and Bank of America. The stock currently trades around $9.57, with analysts forecasting a 'Moderate Buy' consensus and an average target of $20.71." datetime: "2026-07-22T12:12:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293471721.md) - [en](https://longbridge.com/en/news/293471721.md) - [zh-HK](https://longbridge.com/zh-HK/news/293471721.md) --- # Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Needham & Company LLC Analysts at Needham & Company LLC started coverage on shares of Immix Biopharma (NASDAQ:IMMX - Get Free Report) in a report issued on Wednesday, MarketBeat reports. The brokerage set a "buy" rating and a $21.00 price target on the stock. Needham & Company LLC's price target would suggest a potential upside of 119.44% from the stock's current price. Get **Immix Biopharma** alerts: IMMX has been the topic of several other reports. Morgan Stanley assumed coverage on Immix Biopharma in a research report on Wednesday, March 25th. They set an "overweight" rating and a $20.00 target price on the stock. Citigroup began coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They set a "buy" rating for the company. Lifesci Capital initiated coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They issued an "outperform" rating and a $19.00 target price for the company. Bank of America assumed coverage on Immix Biopharma in a research note on Thursday, June 18th. They set a "buy" rating and a $27.00 price objective on the stock. Finally, Mizuho boosted their price objective on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Monday, March 30th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $20.71. **Get Our Latest Stock Report on Immix Biopharma** ## Immix Biopharma Stock Performance Shares of NASDAQ:IMMX opened at $9.57 on Wednesday. The stock has a market capitalization of $520.70 million, a price-to-earnings ratio of -10.40 and a beta of 0.09. The stock's 50-day simple moving average is $9.44 and its two-hundred day simple moving average is $8.48. Immix Biopharma has a 52-week low of $1.94 and a 52-week high of $12.14. Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities analysts forecast that Immix Biopharma will post -0.69 earnings per share for the current fiscal year. ## Hedge Funds Weigh In On Immix Biopharma A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP bought a new stake in shares of Immix Biopharma in the fourth quarter valued at about $30,000. Everhart Financial Group Inc. bought a new position in shares of Immix Biopharma during the second quarter valued at approximately $103,000. Mathes Company Inc. purchased a new position in Immix Biopharma during the fourth quarter valued at approximately $56,000. Balyasny Asset Management L.P. bought a new position in Immix Biopharma in the fourth quarter worth approximately $67,000. Finally, Kera Capital Partners Inc. bought a new position in Immix Biopharma in the fourth quarter worth approximately $68,000. Institutional investors own 11.26% of the company's stock. ## About Immix Biopharma (Get Free Report) Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy. The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment. ## Further Reading - Five stocks we like better than Immix Biopharma - Archer and Anduril Put ACHR Stock on a New Defense Flight Path - PayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued? - Confidence Is Back, But Earnings Show the Consumer Is Being Picky - AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Immix Biopharma Right Now? Before you consider Immix Biopharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list. While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IMMX.US](https://longbridge.com/en/quote/IMMX.US.md) ## Related News & Research - [Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis](https://longbridge.com/en/news/295441199.md) - [Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation](https://longbridge.com/en/news/295383459.md) - [CEA Industries Inc. Regains Compliance with Nasdaq Annual Meeting Requirement | BNC Stock News](https://longbridge.com/en/news/295452696.md) - [Popular (NASDAQ:BPOP) CEO Sells $6,140,050.00 in Stock](https://longbridge.com/en/news/295542398.md) - [Nasdaq Confirmed AGM Group Holdings Inc. Complies with The Nasdaq Listing Rules | AGMH Stock News](https://longbridge.com/en/news/295669211.md)